Chimerix, Inc. (CMRX)
Apr 21, 2025 - CMRX was delisted (reason: acquired by JAZZ)
8.54
-0.01 (-0.12%)
Inactive · Last trade price
on Apr 17, 2025
Chimerix Revenue
In the year 2024, Chimerix had annual revenue of $212.00K, down -34.57%. Chimerix had revenue of $57.00K in the quarter ending December 31, 2024, with 1,325.00% growth.
Revenue (ttm)
$212.00K
Revenue Growth
-34.57%
P/S Ratio
3,778.70
Revenue / Employee
$2,684
Employees
79
Market Cap
801.08M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 212.00K | -112.00K | -34.57% |
Dec 31, 2023 | 324.00K | -33.50M | -99.04% |
Dec 31, 2022 | 33.82M | 31.85M | 1,609.15% |
Dec 31, 2021 | 1.98M | -3.39M | -63.16% |
Dec 31, 2020 | 5.37M | -7.15M | -57.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCMRX News
- 4 weeks ago - Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
- 5 weeks ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
- 7 weeks ago - Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - GlobeNewsWire
- 2 months ago - CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX - Business Wire
- 2 months ago - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - PRNewsWire
- 2 months ago - Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline - Benzinga
- 2 months ago - Jazz Pharmaceuticals to buy Chimerix for $935 million - Reuters